STE
FY2026 Q4 · Calendar Q2 2026
STERIS plc
STERIS delivered a strong fiscal 2026 close with approximately 9% revenue growth to roughly $6 billion, record adjusted EPS of $10.17, and $983 million in free cash flow. Gross margins were modestly pressured by tariffs and inflation, but EBIT margin held at 23.3%. Management struck a confident tone, announcing a dividend increase, a doubled $1 billion share-buyback authorization, and a new $60 million sterility-assurance plant in Ohio. FY27 guidance targets 7-8% revenue growth, ~50 bps of EBIT margin expansion, and EPS of $11.10-$11.30, with tariffs expected to be neutral or slightly positive. The market reacted positively with a 4.6% abnormal move on 2.6x baseline volume.
EPS surprise-0.7%
Market move+4.5%
